Peptide Approaches to Type 1 Diabetes Prevention

Autoimmune Peptide Therapies

0% C-peptide decline

In a phase 1b trial, patients receiving proinsulin peptide injections every 4 weeks showed no decline in C-peptide over 12 months, while placebo patients declined steadily.

Alhadj Ali et al., Science Translational Medicine, 2017

Alhadj Ali et al., Science Translational Medicine, 2017

View as image

Type 1 diabetes (T1D) results from the immune system destroying pancreatic beta cells that produce insulin. By the time of clinical diagnosis, 60-80% of beta cell function is already lost. The central idea behind peptide immunotherapy for T1D is to intervene before that destruction is complete, using fragments of the very proteins that the immune system is attacking (primarily insulin and proinsulin) to retrain T cells toward tolerance rather than destruction. This approach is distinct from the GLP-1 agonist therapies covered elsewhere on this site, because it targets the autoimmune cause rather than metabolic consequences. For a broader view of how peptides can teach immune tolerance across diseases, see our pillar article on peptide therapies for autoimmune disease.

Why Peptide Immunotherapy Could Work Where Other Approaches Have Failed

Conventional immunosuppression (cyclosporine, anti-CD3 antibodies) can slow beta cell destruction but requires broadly suppressing the immune system, which increases infection risk and cannot be sustained long-term. Peptide immunotherapy takes a fundamentally different approach: rather than suppressing the whole immune system, it aims to selectively turn off just the autoreactive T cells that are destroying beta cells.

The concept is based on a well-established immunological principle. When T cells encounter their target antigen (in this case, insulin or proinsulin peptides) in the absence of inflammatory danger signals, they can be driven toward anergy (functional inactivation), deletion, or conversion into regulatory T cells (Tregs) that actively suppress other autoreactive cells. The challenge is delivering the right peptide, at the right dose, through the right route, at the right stage of disease.

Nicholson et al. (1995) provided early proof-of-concept for this approach in a different autoimmune disease. They showed that an altered peptide ligand (APL) based on myelin proteolipid protein prevented autoimmune encephalomyelitis in mice by inducing immune deviation, shifting T-cell responses from destructive Th1 to protective Th2.^[1] This work established the principle that modified peptides could redirect autoimmune responses. The concept has since been applied to T1D using insulin-derived peptides.

Proinsulin Peptide Immunotherapy: The Most Promising Clinical Data

The strongest clinical evidence for peptide immunotherapy in T1D comes from proinsulin peptide trials. Alhadj Ali et al. (2017) published a landmark study in Science Translational Medicine testing intradermal injections of an HLA-DR4-restricted immunodominant proinsulin peptide in newly diagnosed T1D patients.^[2]

The study enrolled patients within 100 days of T1D diagnosis and randomized them to receive the proinsulin peptide every 2 weeks, every 4 weeks, or placebo for 6 months. The key findings:

• Placebo patients showed a steady decline in stimulated C-peptide (a direct measure of remaining beta cell function) at 3, 6, 9, and 12 months versus baseline
• The 4-weekly peptide group showed no decline in C-peptide at any of these time points
• Daily insulin requirements increased by 50% over 12 months in the placebo group but remained unchanged in the treatment groups
• Treatment induced IL-10-producing immune-regulatory responses specific to the proinsulin peptide

The mechanism appears to involve induction of regulatory T cells and a shift from inflammatory to tolerogenic immune responses at the site of injection, which then spreads to affect islet-specific immunity systemically. This is consistent with the concept of tolerogenic peptides redirecting immune responses from destruction to tolerance.

Altered Peptide Ligands: A Cautionary Tale

Not all peptide approaches have succeeded. Altered peptide ligands (APLs) are modified versions of natural autoantigens designed to bind T-cell receptors but deliver a different signal, potentially converting autoreactive T cells from effectors to regulators. The concept worked in animal models but hit problems in human trials.

Walter et al. (2009) conducted a phase 2, randomized, placebo-controlled trial of NBI-6024, an APL based on the insulin B chain (amino acids 9-23), in 188 patients with recently diagnosed T1D.^[3] Patients received subcutaneous injections at three different doses or placebo over 24 months. The trial found no effect on beta cell residual function (measured by C-peptide AUC) or insulin needs at any dose tested.

The failure of NBI-6024 illustrates several challenges in peptide immunotherapy for T1D. The peptide modification may have been insufficient to reliably induce tolerance rather than additional immune activation. The subcutaneous route may not have been optimal. The patients may have been too far into the autoimmune process for peptide immunotherapy alone to reverse the damage. This is the difference between the approach working at the altered peptide ligand level in animal models and in human disease, where heterogeneity in HLA type, disease stage, and immune repertoire adds complexity.

Next-Generation Delivery: Soluble Antigen Arrays

One of the problems with free peptide immunotherapy is controlling the dose that reaches immune cells and the context in which they encounter it. Free peptides injected subcutaneously can be rapidly degraded, distribute unpredictably, and in some cases actually worsen autoimmunity if they activate rather than tolerize T cells.

Firdessa-Fite et al. (2024) addressed this problem by developing soluble antigen arrays (SAgAs): multivalent platforms that display multiple copies of autoantigen peptides on a soluble scaffold.^[4] In the NOD mouse model of spontaneous autoimmune diabetes, SAgAs protected against disease onset more effectively than equivalent free peptide injections. The multivalent display improved the efficiency of T-cell tolerance induction and reduced the risk of off-target immune activation.

This work suggests that the failure of early peptide immunotherapy trials like NBI-6024 may have been partly a delivery problem rather than a fundamental flaw in the approach. Reformulating peptides into optimized delivery platforms could improve both efficacy and safety.

The Gut-Immune Connection: How T1D May Start

Understanding how T1D begins is critical for designing effective peptide prevention strategies. Chen et al. (2026) reviewed evidence that molecular mimicry between gut microbial peptides and islet autoantigens may trigger the initial autoimmune response.^[5]

The hypothesis is that in genetically susceptible individuals (those with certain HLA types), T cells that respond to microbial peptides in the gut can cross-react with structurally similar peptides on pancreatic beta cells. The gut microbiome thus becomes a potential trigger for T1D, and microbial peptides may be the "first antigen" that launches the autoimmune cascade. This has implications for peptide immunotherapy design: the target peptides may need to account not only for insulin/proinsulin sequences but also for the microbial peptides that initiated the response.

Tolerogenic Dendritic Cells: A Neuropeptide Approach

An alternative to direct peptide injection is using neuropeptides to generate tolerogenic antigen-presenting cells. Delgado et al. (2009) showed that the neuropeptide VIP (vasoactive intestinal peptide) can drive dendritic cells toward a tolerogenic phenotype that induces regulatory T cells rather than effector T cells.^[6]

VIP-conditioned dendritic cells express lower levels of co-stimulatory molecules and produce more IL-10 and less IL-12, creating an environment that favors immune tolerance. When loaded with islet autoantigens and administered to pre-diabetic mice, these cells can delay or prevent diabetes onset. This approach combines a neuropeptide's immunomodulatory properties with antigen-specific tolerance induction, potentially offering a more controlled way to deliver peptide immunotherapy.

The Broader Therapeutic Landscape

Zheng et al. (2026) reviewed the full range of approaches being developed to preserve or restore beta cell function in T1D.^[7] The peptide and protein-based strategies include:

• Proinsulin peptides (intradermal injection, as in the Alhadj Ali trial)
• GAD-alum (GAD65 protein formulated with aluminum hydroxide adjuvant, currently in phase 3 trials as Diamyd)
• Anti-CD3 antibodies (teplizumab/Tzield, FDA-approved in 2022 to delay T1D onset in at-risk individuals by a median of 2-3 years)
• Soluble antigen arrays (multivalent peptide platforms, preclinical)
• Combination approaches (peptide immunotherapy plus low-dose anti-inflammatory agents)

Infante et al. (2025) also explored whether incretin-based therapies (semaglutide, tirzepatide) could preserve beta cell function in T1D through metabolic and anti-inflammatory mechanisms distinct from immune tolerance.^[8] These GLP-1 agonists work through different pathways than peptide immunotherapy but could potentially be combined with tolerance-inducing approaches.

The Timing Problem: When Peptide Immunotherapy Can Still Help

One of the central challenges in T1D peptide immunotherapy is the timing of intervention. The autoimmune destruction of beta cells begins years before clinical symptoms appear. By the time a patient develops hyperglycemia and is diagnosed, most beta cells are already gone.

T1D progression is now understood in three stages. Stage 1 involves the presence of two or more islet autoantibodies with normal blood sugar. Stage 2 shows autoantibodies plus abnormal glucose tolerance but no symptoms. Stage 3 is clinical diabetes with symptoms. Screening for autoantibodies can identify at-risk individuals years before stage 3.

Peptide immunotherapy is theoretically most effective at stages 1 and 2, when substantial beta cell mass remains and the autoimmune process can still be redirected. The Alhadj Ali trial enrolled patients within 100 days of diagnosis (early stage 3), which may explain why it showed preservation rather than improvement of beta cell function. Trials in stage 1 and stage 2 individuals are being planned but face recruitment challenges because these people are currently asymptomatic.

The GAD-alum (Diamyd) program has addressed this by focusing on genetically defined subgroups (HLA DR3-DQ2 positive patients) who are most likely to respond, with a pivotal phase 3 trial (DIAGNODE-3) ongoing across Europe and the United States. This represents the most advanced peptide/protein immunotherapy trial currently in progress for T1D prevention.

Where the Field Stands

Peptide immunotherapy for T1D prevention has biological rationale, animal model validation, and early positive human data. The proinsulin peptide trial (Alhadj Ali 2017) showed genuine beta cell preservation, though in a small study. The NBI-6024 failure demonstrates that not all peptide approaches will work, and delivery, dose, and timing all matter.

The field is moving toward combination strategies (peptide immunotherapy plus anti-inflammatory agents), better delivery platforms (soluble antigen arrays), and earlier intervention (in at-risk individuals before clinical diagnosis). The approval of teplizumab for T1D delay validates the concept that immune modulation can meaningfully change the disease course. Peptide-based approaches aim to achieve similar results with greater precision and fewer off-target immune effects.

The Bottom Line

Peptide immunotherapy for T1D aims to retrain the immune system using fragments of the autoantigens it attacks. Proinsulin peptide injections preserved beta cell function in a small clinical trial, while the altered peptide ligand NBI-6024 failed in phase 2. Next-generation approaches include soluble antigen arrays for safer delivery and neuropeptide-conditioned tolerogenic dendritic cells. The field is moving toward earlier intervention, combination therapies, and improved delivery platforms.

Frequently Asked Questions

Can peptide immunotherapy prevent type 1 diabetes?

Peptide immunotherapy has shown early promise in preserving beta cell function in newly diagnosed T1D. A 2017 trial using proinsulin peptide injections showed no decline in C-peptide (a measure of insulin production) over 12 months, while placebo patients declined steadily (Alhadj Ali et al., Science Translational Medicine). Larger trials are needed before this approach could be used for prevention, and intervention timing appears critical.

What is proinsulin peptide immunotherapy?

Proinsulin peptide immunotherapy involves injecting small fragments of proinsulin (the precursor to insulin) into the skin to retrain the immune system. The goal is to induce regulatory T cells that suppress the autoimmune attack on beta cells, rather than activating destructive T cells. A phase 1b trial showed the approach preserved beta cell function and stabilized insulin requirements over 12 months.

Why did the NBI-6024 peptide trial fail for type 1 diabetes?

The NBI-6024 altered peptide ligand, based on the insulin B chain, failed to preserve beta cell function in 188 newly diagnosed T1D patients over 24 months (Walter et al., 2009). Possible reasons include: the peptide modification was insufficient to reliably induce tolerance; the subcutaneous route may not have been optimal; and patients may have been too late in disease progression for peptide therapy alone to work.

What are soluble antigen arrays for diabetes?

Soluble antigen arrays (SAgAs) are multivalent platforms that display multiple copies of autoantigen peptides on a soluble scaffold. In the NOD mouse model of autoimmune diabetes, SAgAs protected against disease onset more effectively than free peptide injections and with better safety (Firdessa-Fite et al., 2024). They represent a next-generation approach to peptide immunotherapy that addresses delivery and dosing challenges.

Is teplizumab a peptide therapy for diabetes?

Teplizumab (Tzield) is a monoclonal antibody targeting CD3 on T cells, not a peptide. It was FDA-approved in 2022 to delay the onset of clinical T1D in at-risk individuals by approximately 2-3 years. While not a peptide therapy itself, its approval validates the concept that immune modulation can change the T1D disease course, which supports the rationale for more targeted peptide-based approaches.

How does the gut microbiome connect to type 1 diabetes peptide research?

Gut microbial peptides that structurally resemble islet autoantigens may trigger autoimmunity through molecular mimicry in genetically susceptible individuals (Chen et al., Immunology, 2026). T cells primed against these microbial peptides can cross-react with pancreatic beta cell proteins. This suggests that peptide immunotherapy designs may need to account for microbial trigger peptides in addition to insulin and proinsulin sequences.